ArticleJournal of translational medicine2025
Kynurenine-mediated redox regulation provides neuroprotection in central retinal artery occlusion.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCentral retinal artery occlusion (CRAO) causes irreversible vision loss through ischemia-reperfusion (I/R) injury, characterized by oxidative stress and retinal ganglion cell (RGC) death. Current therapies are inadequate. This study investigates kynurenine (Kyn)—a tryptophan metabolite—as a novel therapeutic agent targeting dual pathways to combat retinal I/R injury.
methodsThe unilateral pterygopalatine ophthalmic artery occlusion (UPOAO) model was established by inserting a silicone filament embolus into the pterygopalatine artery. The detection of tryptophan metabolites in serum and retinal tissues was carried out using metabolomics. In the UPOAO mouse model, kynurenine (Kyn) was administered via intravitreal injection. Simultaneously, R28 retinal cells were treated with Kyn during oxygen-glucose deprivation (OGD) induction to model ischemic injury in vitro. Electroretinography (ERG) was performed to examine the visual function of the mice. Western blot analysis and immunofluorescence were used to detect the apoptosis level of retinal ganglion cells (RGCs). The role of Kyn in activating the aryl hydrocarbon receptor (AhR) to reduce oxidative stress in RGCs was demonstrated by using an AhR inhibitor.
resultsThe neuroprotective effects of Kyn are mediated by a dual pathway: activation of the AhR-Nrf2 signaling axis, which transcriptionally upregulates antioxidant genes to mitigate oxidative stress, and modulation of downstream kynurenine pathway (KP) metabolites. While AhR-Nrf2 signaling provides transcriptional support for redox homeostasis, KP metabolites directly scavenge reactive oxygen species, synergistically counteracting oxidative damage and energy deficits in RIR injury.
conclusionsOur findings highlight Kyn as a pathway-specific therapeutic candidate for CRAO, with potential for receptor-targeted and metabolic modulation strategies in treating retinal ischemia-reperfusion injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.